Blackfynn, a life sciences company developing a proprietary data integration and analytics platform to accelerate the development of therapeutics for neurologic disease, has secured two highly competitive direct-to-Phase 2 Small Business Innovation Research (SBIR) grants from the Defense Advanced Research Projects Agency (DARPA) and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The combined grants have the potential to provide approximately $3M in funding to Blackfynn over three years. Blackfynn also announced a collaboration with Ripple, a leading innovator in neural interfaces and medical devices.
The DARPA grant will expand Blackfynn’s capabilities to handle device data with reduced latency, allowing rapid integration and analysis of streaming time-series data from any implanted device or sensor. This has applicability across a wide variety of neuromodulatory devices, including devices to sense and treat seizures, Parkinson’s Disease, depression and others, by sensing, interpreting and modulating neural input to key areas in the brain and peripheral nervous system.
Our work with NIDA will expand the Blackfynn data platform to accelerate translational research in addiction science, focusing on identifying novel combination biomarkers and mechanisms from integrated brain imaging, genomics, neurophysiology and clinical data. This may enable rapid identification of targets, grounded in disease physiology, for drug development.
Under the Ripple collaboration, Blackfynn will extend its proprietary data integration and analysis platform to handle streaming data from Ripple devices, detect relevant events, and adjust device parameters, all in real time. This work builds on the Blackfynn platform’s strong foundational capabilities and will advance our work toward developing closed-loop control of medical devices.
Taken together, the Ripple collaboration and SBIR funding will accelerate the growth of the Blackfynn platform, the expansion of our engineering and scientific teams, and advance applications toward disease modifying therapeutics.
Blackfynn has developed the leading data integration and analysis platform to transform the treatment of neurological diseases. We use our platform and expert team to drive development of disease-modifying therapeutic drugs, enable personalized therapeutic devices and accelerate translational research. Blackfynn has collaborations in place with Marinus Pharmaceuticals, the Epilepsy Study Consortium, the NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, the Children's Hospital of Philadelphia (CHOP), DARPA, NIDA and dozens of academic labs and institutions worldwide. For more information, visit www.blackfynn.com.